NCT05262608 - The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

February 26, 2024

Study Completion Date

April 26, 2024

Conditions

Prostate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Olaparib

Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily

Trial Locations (1)

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou